BRPI0417732A - aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma - Google Patents

aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma

Info

Publication number
BRPI0417732A
BRPI0417732A BRPI0417732-0A BRPI0417732A BRPI0417732A BR PI0417732 A BRPI0417732 A BR PI0417732A BR PI0417732 A BRPI0417732 A BR PI0417732A BR PI0417732 A BRPI0417732 A BR PI0417732A
Authority
BR
Brazil
Prior art keywords
glaucoma
diagnosis
identification
treatment
serum amyloid
Prior art date
Application number
BRPI0417732-0A
Other languages
English (en)
Inventor
Abbot F Clark
Wan-Heng Wang
Loretta Mcnatt
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0417732A publication Critical patent/BRPI0417732A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"APLICAçãO DE GENE AMILóIDE A SéRICO NO DIAGNóSTICO E TRATAMENTO DO GLAUCOMA E IDENTIFICAçãO DE AGENTES ANTIGLAUCOMA". A presente invenção refere-se proporcionar composições e métodos para tratar glaucoma, métodos para diagnosticar glaucoma, e métodos para identificar agentes os quais podem ser úteis no tratamento do glaucoma. Mais especificamente, a presente invenção descreve a aplicação de agentes que modulam a expressão de amilóide A sérica.
BRPI0417732-0A 2003-12-17 2004-12-01 aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma BRPI0417732A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53043003P 2003-12-17 2003-12-17
PCT/US2004/040156 WO2005060542A2 (en) 2003-12-17 2004-12-01 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Publications (1)

Publication Number Publication Date
BRPI0417732A true BRPI0417732A (pt) 2007-04-03

Family

ID=34710163

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417732-0A BRPI0417732A (pt) 2003-12-17 2004-12-01 aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma

Country Status (13)

Country Link
US (3) US7357931B2 (pt)
EP (1) EP1694192A4 (pt)
JP (2) JP4827742B2 (pt)
CN (1) CN1993136A (pt)
AR (2) AR048135A1 (pt)
AU (1) AU2004304944B2 (pt)
BR (1) BRPI0417732A (pt)
CA (1) CA2545777A1 (pt)
MX (1) MXPA06006503A (pt)
RU (1) RU2365379C2 (pt)
TW (1) TWI398261B (pt)
WO (1) WO2005060542A2 (pt)
ZA (1) ZA200603464B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121039A1 (en) * 2004-12-07 2006-06-08 Alcon, Inc. Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20050137122A1 (en) * 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
WO2007062101A2 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20110067123A1 (en) * 2008-02-19 2011-03-17 Julie Andersen Mao-b elevation as an early parkinson's disease biomarker
RU2404253C1 (ru) * 2009-06-22 2010-11-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" СПОСОБ ОБНАРУЖЕНИЯ МУТАЦИИ P369ins В ГЕНЕ CYP1B1
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
TWI472369B (zh) * 2012-07-24 2015-02-11 Univ Nat Central 分析套組及分析方法
AU2014244154B2 (en) * 2013-03-14 2018-08-09 EyeCRO, LLC Microemulsion topical delivery platform
WO2017082393A1 (ja) * 2015-11-12 2017-05-18 学校法人 聖マリアンナ医科大学 緑内障予防治療剤
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
CN108299551A (zh) * 2018-02-09 2018-07-20 北京市华信行生物科技有限公司 血清淀粉样蛋白a1突变体及其制备方法和应用
CN113244225B (zh) * 2021-06-16 2022-06-28 昆明医科大学第一附属医院 土槿皮乙酸在制备抗血小板药物中的应用
CN113186275A (zh) * 2021-06-16 2021-07-30 上海交通大学医学院附属仁济医院 血清淀粉样蛋白a1在制备作为诊断多囊卵巢综合征的生物标记物中的用途
CZ2021389A3 (cs) * 2021-08-20 2022-03-16 GeneSpector Innovations s.r.o. Způsob predikce závažnosti průběhu infekčního onemocnění a biomarker pro použití při provádění tohoto způsobu a monitoringu terapie infekčního onemocnění

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5606043A (en) * 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
US7718697B2 (en) * 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途

Also Published As

Publication number Publication date
WO2005060542A2 (en) 2005-07-07
US7357931B2 (en) 2008-04-15
US20090036371A1 (en) 2009-02-05
AU2004304944B2 (en) 2010-06-10
US20050153927A1 (en) 2005-07-14
CN1993136A (zh) 2007-07-04
EP1694192A4 (en) 2010-12-08
RU2006125428A (ru) 2008-01-27
JP2007514783A (ja) 2007-06-07
RU2365379C2 (ru) 2009-08-27
AU2004304944A1 (en) 2005-07-07
MXPA06006503A (es) 2008-02-13
US20120064532A1 (en) 2012-03-15
ZA200603464B (en) 2007-07-25
WO2005060542A3 (en) 2006-10-26
CA2545777A1 (en) 2005-07-07
JP2011157398A (ja) 2011-08-18
AR048135A1 (es) 2006-04-05
TWI398261B (zh) 2013-06-11
TW200520768A (en) 2005-07-01
EP1694192A2 (en) 2006-08-30
AR077599A2 (es) 2011-09-07
JP4827742B2 (ja) 2011-11-30

Similar Documents

Publication Publication Date Title
MX2009004402A (es) Uso de gen de amiloide serico en el diagnostico y tratamiento de glaucoma e identificacion de agentes anti-glaucoma.
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
CY1112579T1 (el) Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδας
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
WO2005060542A3 (en) Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
BRPI0416447A (pt) lentes de contato hìbridas
BRPI0209792B8 (pt) anticorpo anti-vla-1, composição que o compreende, ácido nucléico e vetor, bem como métodos in vitro para determinar o nível de vla-1 em tecido e para identificar inibidor de domínio i de integrina
MA29528B1 (fr) Agents de fixation
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
ATE324106T1 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
WO2003103581A3 (en) Compositions and methods for liver growth and liver protection
MA29787B1 (fr) Traitement de maladies auto-immunes
WO2022104136A3 (en) Methods and compositions for tauopathy diagnosis and treatment
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
BR0210650A (pt) Tablete, e, uso do mesmo
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
BRPI0807601B8 (pt) método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos
BR0303912A (pt) Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável
WO2003070883A3 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
BR0312795A (pt) Apresentação farmacêutica de sumatriptan, processo para sua preparação e método para tratar a enxaqueca
BR0313150A (pt) Cápsulas de gelatina que exibem ligação reticulada reduzida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]